210 related articles for article (PubMed ID: 6686617)
1. A review of cis-platinum ototoxicity.
Moroso MJ; Blair RL
J Otolaryngol; 1983 Dec; 12(6):365-9. PubMed ID: 6686617
[TBL] [Abstract][Full Text] [Related]
2. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.
Reddel RR; Kefford RF; Grant JM; Coates AS; Fox RM; Tattersall MH
Cancer Treat Rep; 1982 Jan; 66(1):19-23. PubMed ID: 7198012
[TBL] [Abstract][Full Text] [Related]
3. Ototoxicity of cis-diamminedichloroplatinum.
Vodvárka P; Foukalová J; Mrázek J; Philippová J
Neoplasma; 1985; 32(2):229-38. PubMed ID: 4039797
[TBL] [Abstract][Full Text] [Related]
4. Neurochemistry of the peripheral and central auditory system after ototoxic drug exposure: implications for tinnitus.
Rybak LP
Int Tinnitus J; 2005; 11(1):23-30. PubMed ID: 16419684
[TBL] [Abstract][Full Text] [Related]
5. [Cisplatin ototoxicity. A clinical study].
Schröder M; Laskawi R; Stennert E; Kühnle H; Thiele FW
Laryngol Rhinol Otol (Stuttg); 1986 Feb; 65(2):86-9. PubMed ID: 3959692
[TBL] [Abstract][Full Text] [Related]
6. [Tinnitus in the diagnosis and prognosis of ototoxicity].
Doménech J; Carulla M; Traserra J
Acta Otorrinolaringol Esp; 1990; 41(1):7-9. PubMed ID: 2337487
[TBL] [Abstract][Full Text] [Related]
7. Bromate-induced ototoxicity.
Campbell KC
Toxicology; 2006 Apr; 221(2-3):205-11. PubMed ID: 16460859
[TBL] [Abstract][Full Text] [Related]
8. [Ototoxicity of cisplatin in children with malignant diseases].
Hadjilaskari P; Fengler R; Hartmann R; Henze G
Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
[TBL] [Abstract][Full Text] [Related]
9. cis-Diamminedichloroplatinum: a cytostatic with an ototoxic effect.
Hartwig S; Pettersson U; Stahle J
ORL J Otorhinolaryngol Relat Spec; 1983; 45(5):257-61. PubMed ID: 6684750
[TBL] [Abstract][Full Text] [Related]
10. Cochlear structure and function after round window application of ototoxins.
Bauer CA; Brozoski TJ
Hear Res; 2005 Mar; 201(1-2):121-31. PubMed ID: 15721567
[TBL] [Abstract][Full Text] [Related]
11. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing.
Kopelman J; Budnick AS; Sessions RB; Kramer MB; Wong GY
Laryngoscope; 1988 Aug; 98(8 Pt 1):858-64. PubMed ID: 3398663
[TBL] [Abstract][Full Text] [Related]
12. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
13. cis-platinum ototoxicity in children.
Pasic TR; Dobie RA
Laryngoscope; 1991 Sep; 101(9):985-91. PubMed ID: 1886448
[TBL] [Abstract][Full Text] [Related]
14. [The cochlea: modern physiologic insights into sensorineural hearing loss].
Frijns JH; Schoonhoven R
Ned Tijdschr Geneeskd; 1998 Apr; 142(15):830-6. PubMed ID: 9623155
[TBL] [Abstract][Full Text] [Related]
15. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
[TBL] [Abstract][Full Text] [Related]
16. Erythromycin associated hearing loss in a patient with prior cis-platinum induced ototoxicity.
Wallach PM; Love SR; Fiorica JV; Hoffman MS; Flannery MT
J Fla Med Assoc; 1992 Dec; 79(12):821-2. PubMed ID: 1474367
[TBL] [Abstract][Full Text] [Related]
17. Correlations between cis-platinum dosage and toxicity in a guinea pig model.
Hoeve LJ; Mertens zur Borg IR; Rodenburg M; Brocaar MP; Groen BG
Arch Otorhinolaryngol; 1988; 245(2):98-102. PubMed ID: 3390078
[TBL] [Abstract][Full Text] [Related]
18. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration.
Waters GS; Ahmad M; Katsarkas A; Stanimir G; McKay J
Ear Hear; 1991 Apr; 12(2):91-102. PubMed ID: 2065844
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
20. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
